Metreleptin is a leptin analogue used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients various forms of lipodystrophy. Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy.
- Mechanism
- Curator reviewed · 2 references
Metreleptin is an analog of an endogenous hormone, leptin, which is secreted by adipose tissue and helps to regulate satiety. Metreleptin mimics the physiological effects of leptin by binding to and activating the human leptin receptor (ObR).
- Primary indication
- Metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.Curator reviewed · 5 structured indications
- Formula / weight
- C714H1167N191O221S6 · 16155.4429 Da
- First approval
- Canada, 2024 · United States, 2014 · European Union, 2020
- Also known as
- N-Methionylleptin · r-metHuLeptin
- Code names
- Leptin A-100 · Mettreleptin
- Brand names
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with Metreleptin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account